IPSEN (EPA:IPN) | Finanzwire

Basculer en Français

10885	Companies
236936	Keywords
165834	Articles
127157	Press releases

Home
Companies
IPSEN

BRIEF

published on 08/21/2026 at 07:05, 5 days 19 hours ago

Ipsen strengthens its oncology offering with the acquisition of Kartos Therapeutics

Oncology Ipsen Myelofibrosis Navtemadlin Kartos Therapeutics
BRIEF

published on 08/21/2026 at 07:05, 5 days 19 hours ago

Ipsen Acquires Kartos Therapeutics, Bolsters Oncology Pipeline

Oncology Pipeline Ipsen Myelofibrosis Navtemadlin Kartos Therapeutics
PRESS RELEASE

published on 08/21/2026 at 07:00, 5 days 19 hours ago

Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline. Acquisition includes Phase III clinical development of MDM2 inhibitor navtemadlin for myelofibrosis patients

Acquisition Oncology Pipeline Ipsen Navtemadlin Kartos Therapeutics
BRIEF

published on 08/20/2026 at 18:05, 6 days 8 hours ago

Evolution of Ipsen's Share Capital in July 2026

Euronext Paris Share Capital Voting Rights Actions Ipsen
BRIEF

published on 08/20/2026 at 18:05, 6 days 8 hours ago

IPSEN Provides Update on Voting Rights and Share Capital for July 2026

Euronext Paris Share Capital Voting Rights Ipsen July 2026
PRESS RELEASE

published on 08/20/2026 at 18:00, 6 days 8 hours ago

Ipsen - July 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information on total number of voting rights and shares for a company listed on Euronext Paris

Euronext Paris Voting Rights Shares ISIN Code Total Number
BRIEF

published on 07/24/2026 at 10:01, 1 month 2 days ago

BlackRock Inc. reduces its stake in IPSEN SA

Voting Rights Actions BlackRock Threshold Crossing Ipsen SA
BRIEF

published on 07/24/2026 at 07:05, 1 month 2 days ago

Update on Ipsen's Phase III BOLD Trial in Biliary Atresia

Clinical Research Biliary Atresia Phase III BOLD Trial Odevixibat Liver Transplantation
PRESS RELEASE

published on 07/24/2026 at 07:00, 1 month 2 days ago

Ipsen provides update on Phase III BOLD trial in biliary atresia
Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care

Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF

published on 07/09/2026 at 07:05, 1 month 17 days ago

Positive Phase III Results for Dysport® in the Treatment of Migraine

Phase III Dysport Episodic Migraine Chronic Migraine Botulinum Toxin

1 2 ... 6

Accesswire

Published on 08/27/2026 at 02:00, 9 minutes ago

Algo Grande Copper Announces Upsizing of Private Placement
Published on 08/27/2026 at 00:05, 2 hours 4 minutes ago

Kidoz Reports Record Q2 2026 Revenue, up 37%, as H1 Revenue Reaches US$6.28 Million (CAD$8.66 Million)
Published on 08/26/2026 at 23:00, 3 hours 9 minutes ago

Datametrex Announces Transition to Semi-Annual Financial Reporting
Published on 08/26/2026 at 22:30, 3 hours 39 minutes ago

AI/ML Innovations Inc. Closes First Tranche of Private Placement
Published on 08/26/2026 at 22:30, 3 hours 39 minutes ago

Blueberries Medical Announces Closing of C$1.1 Million Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 08/26/2026 at 23:05, 3 hours 4 minutes ago

Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta
Published on 08/26/2026 at 18:44, 7 hours 24 minutes ago

AUSTRIACARD HOLDINGS AG: Press Release H1 2026 Financial Results
Published on 08/26/2026 at 18:40, 7 hours 29 minutes ago

MBC GROUP REVEALS MBC GAMES STUDIO WITH DEBUT TITLE UNVEILING AT GAMESCOM
Published on 08/26/2026 at 18:30, 7 hours 39 minutes ago

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Published on 08/26/2026 at 18:00, 8 hours 9 minutes ago

MHM Corporate: reduces the nominal value of its shares to €0.011

Les Echos

Published on 08/26/2026 at 18:02, 8 hours 7 minutes ago

Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:00, 8 hours 9 minutes ago

Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Published on 08/26/2026 at 17:40, 8 hours 29 minutes ago

First half 2026 results
Published on 08/25/2026 at 17:45, 1 day 8 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 08/25/2026 at 17:45, 1 day 8 hours ago

Imerys-08-2026-information-share-capital-and-voting-rights-as-of-31-July-2026

View all LES ECHOS COMFI WIRE